Clinical trial tests feasibility of targeting particular classes of tumor types with certain drugs

February 2, 2018 by Bob Yirka, Medical Xpress report
Credit: CC0 Public Domain

A large team of researchers from the U.S., Spain and Australia has found that the efficacy of drugs for treating cancer aimed at targeting particular classes of mutations depends on the type of tumor tissue involved and the nature of the mutations. In their paper published in Nature, the team describes the clinical trial and the results they have seen thus far. Elaine Mardis with the Institute for Genomic Medicine, Nationwide Children's Hospital, in Columbus, Ohio, offers a News & Views piece in the same journal issue outlining the study, and general research of abnormalities in genes linked to cancer and possible new treatment options.

In the past, doctors treated all patients with similar types of cancers in much the same way, but more recent research has shown this is not likely the best approach. This is because not all tumors for specific cancers are alike. As an example, not all lung tumors are the same—their cause and development can vary between patients. For this reason, scientists have been looking for ways to develop customized treatments based on an individual's circumstances. As this new approach has progressed, scientists have found that much of the difference between tumors can be traced back to differences in genes. In this new effort, the researchers have focused on mutations in the ERBB2 and ERBB3 genes because some of them have been found to overexpress HER2 proteins as part of .

To learn more about the role ERBB2 and ERBB3 play in development, the researchers gave a drug called neratinib to 141 patients with 21 types of cancer (and 42 kinds of mutations) in their clinical trial—it blocks the production of HER2 proteins. They have found that the effectiveness of the drug varied depending on mutational and tissue contexts. Some patients with ERBB2 mutations, they report, responded well to the drug, particularly those with tumors containing alterations in amino acids in extracellular or kinase HER2 domains. Others with tumors expressing HER2 proteins did not respond as well, and those with ERBB3 genes saw no change at all.

The researchers suggest their study has thus far shown that therapies designed to target certain classes of will have to take into account tumor tissue and the nature of the tumors involved.

Explore further: New statistical analysis reveals thousands of rare mutations linked with cancer

More information: David M. Hyman et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers, Nature (2018). DOI: 10.1038/nature25475

Abstract
Somatic mutations of ERBB2 and ERBB3 (which encode HER2 and HER3, respectively) are found in a wide range of cancers. Preclinical modelling suggests that a subset of these mutations lead to constitutive HER2 activation, but most remain biologically uncharacterized. Here we define the biological and therapeutic importance of known oncogenic HER2 and HER3 mutations and variants of unknown biological importance by conducting a multi-histology, genomically selected, 'basket' trial using the pan-HER kinase inhibitor neratinib (SUMMIT; clinicaltrials.gov identifier NCT01953926). Efficacy in HER2-mutant cancers varied as a function of both tumour type and mutant allele to a degree not predicted by preclinical models, with the greatest activity seen in breast, cervical and biliary cancers and with tumours that contain kinase domain missense mutations. This study demonstrates how a molecularly driven clinical trial can be used to refine our biological understanding of both characterized and new genomic alterations with potential broad applicability for advancing the paradigm of genome-driven oncology.

Related Stories

New statistical analysis reveals thousands of rare mutations linked with cancer

April 20, 2017
Scientists have identified thousands of previously ignored genetic mutations that, although rare, likely contribute to cancer growth. The findings, which could help pave the way to new treatments, are published in PLOS Computational ...

Investigators match novel cancer mutations with potential therapies

August 4, 2017
Research led by Vanderbilt-Ingram Cancer Center (VICC) investigators may have solved a mystery about why a targeted therapy stops working in a small group of breast cancer patients.

Study finds breast cancer driver, HER2, in 3 percent of lung cancers

July 27, 2017
The Lung Cancer Mutation Consortium at the University of Colorado Cancer Center reports this week in the journal Cancer that 24 of 920 patients (3 percent) with advanced-stage lung cancer had mutations in the gene HER2. Seventy-one ...

A new HER2 mutation, a clinical trial and a promising diagnostic tool for metastatic breast cancer

August 1, 2017
There is a group of metastatic breast cancers that has the HER2 gene amplified - the cells have many copies of it - which leads to enhanced activity of the product enzyme, a tyrosine kinase. HER2 has been established as a ...

Breast cancer cells found to switch molecular characteristics

August 24, 2016
A study led by Massachusetts General Hospital (MGH) investigators reveals how spontaneous changes in the molecular characteristics of tumors can lead to tumors with a mixed population of cells requiring treatment with several ...

Abnormalities in HER2 gene found in wide variety of advanced cancers

June 2, 2013
The HER2 growth-factor gene is known to be over-active in breast and gastro-esophageal cancers. But now, irregularities in the genes 's expression—among them mutations, amplifications, substitutions, and translocations—have ...

Recommended for you

Healthy diets linked to better outcomes in colorectal cancer

October 20, 2018
Colorectal cancer patients who followed healthy diets had a lower risk of death from colorectal cancer and all causes, even those who improved their diets after being diagnosed, according to a new American Cancer Society ...

Why some cancers affect only young women

October 19, 2018
Among several forms of pancreatic cancer, one of them specifically affects women, often young. How is this possible, even though the pancreas is an organ with little exposure to sex hormones? This pancreatic cancer, known ...

Scientists to improve cancer treatment effectiveness

October 19, 2018
Together with researchers from the University of Nantes and the University of Reims Champagne-Ardenne in France, experts from the National Research Nuclear University MEPhI have recently developed a quantum dot-based microarray ...

Mutant cells colonize our tissues over our lifetime

October 18, 2018
By the time we reach middle age, more than half of the oesophagus in healthy people has been taken over by cells carrying mutations in cancer genes, scientists have uncovered. By studying normal oesophagus tissue, scientists ...

Study involving hundreds of patient samples may reveal new treatment options of leukemia

October 17, 2018
After more than five years and 672 patient samples, an OHSU research team has published the largest cancer dataset of its kind for a form of leukemia. The study, "Functional Genomic Landscape of Acute Myeloid Leukemia", published ...

A 150-year-old drug might improve radiation therapy for cancer

October 17, 2018
A drug first identified 150 years ago and used as a smooth-muscle relaxant might make tumors more sensitive to radiation therapy, according to a recent study led by researchers at The Ohio State University Comprehensive Cancer ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.